Vergoeding 2015-2019 voor ATC-subgroep C10AX : Overige antilipaemica
- Raming voor de totale Zvw-populatie
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| C10AX09 Ezetimib (Ezetrol ®) | 31.435.800 | 35.553.800 | 40.014.000 | 28.133.100 | 7.298.500 |
| C10AX12 Lomitapide (Lojuxta ®) | 188.160 | 1.196.600 | 1.233.400 | 1.499.400 | 1.491.100 |
| C10AX13 Evolocumab (Repatha ®) | . | 5.752.200 | 20.209.900 | 33.380.700 | 39.972.700 |
| C10AX14 Alirocumab (Praluent ®) | . | 1.933.100 | 9.789.700 | 20.152.500 | 30.215.700 |
| Totaal | 31.623.960 | 44.435.700 | 71.247.000 | 83.165.700 | 78.978.000 |